☆ 4.6 Article

A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes

BRITISH JOURNAL OF HAEMATOLOGY (2009)

Journal

BRITISH JOURNAL OF HAEMATOLOGY

Volume 147, Issue 5, Pages 681-685

Publisher

WILEY

DOI: 10.1111/j.1365-2141.2009.07893.x

Keywords

hypereosinophilia; FIP1L1 rearrangement; imatinib; response kinetics

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

P>Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with FIP1L1-PDGRFA rearrangement and 5/17 without, P = 0 center dot 006), most after 2 weeks of 100 mg/d imatinib. The maximum imatinib dose had no effect in early unresponsive patients. Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Clinical Neurology

FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction

Juliette Tennenbaum, Matthieu Groh, Laura Venditti, France Campos-Gazeau, Emilie Chalayer, Thomas De Broucker, Mohamed Hamidou, Mathilde Hunault, Aicha Lyoubi, Raphaelle Meunier, Thierry Muron, Damien Sene, Borhane Slama, Celine Guidoux, Guillaume Lefevre, Jean-Emmanuel Kahn, Christian Denier, Julien Rohmer

Summary: Ischemic stroke has been reported in patients with F/P-associated clonal hypereosinophilic syndrome, and most cerebral imaging shows multiple bilateral infarctions of watershed distribution. Despite frequent cardiac involvement, only one patient had evidence of cardiac thrombus, and 62.5% of strokes were presumed to be of undetermined etiology according to the TOAST classification. After a median follow-up of 4.5 years, stroke recurred in only 3 out of 15 patients treated with imatinib.

STROKE (2021)

Add to Collection

Article Dermatology

Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases

Valentina Bellani, Giorgio Alberto Croci, Cristina Bucelli, Carlo Alberto Maronese, Sara Alberti, Alessandra Iurlo, Daniele Cattaneo

Summary: Lymphomatoid papulosis (LyP) is a benign condition that can be associated with hematologic diseases. Hypereosinophilic syndromes are a group of disorders characterized by high levels of eosinophils in the blood. In this case report, two patients with LyP and myeloid neoplasm with eosinophilia achieved complete remission of both conditions after starting treatment with imatinib.

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Medical Laboratory Technology

Hematological hypereosinophilia

Ines Ghariani, Oumaima Mahmoud, Saloua Hamzaoui, Nejia Braham, Leila Bekir

Summary: Hematological hypereosinophilia is a rare and complex pathology with epidemiological, clinical, biological, and therapeutic heterogeneity. This study identified the clinical manifestations, etiology, and abnormalities in blood pictures, and emphasized the contribution of molecular biology in the diagnosis and treatment.

ANNALES DE BIOLOGIE CLINIQUE (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Switchable light vs. acid-induced transformations of complex framework compounds at room temperature

Maxim S. Kobzev, Alexander A. Titov, Tatiana N. Borisova, Leonid G. Voskressensky, Alexey V. Varlamov, Massimo Christian D'Alterio, Alessio Petrone, Rafael Luque, Giovanni Talarico

Summary: This article presents a novel and original protocol for the preparation of complex framework compounds containing a vinylcyclopropane (VCP) fragment. The method involves UV conversion of cyclopentene (CP) derivatives under standard conditions to achieve high yields of target products. Additionally, a one-pot approach for the synthesis of VCPs and the mechanisms of mutual rearrangements of both VCP and CP have been rationalized using DFT calculations.

GREEN CHEMISTRY (2022)

Add to Collection

Article Multidisciplinary Sciences

Hypereosinophilia causes progressive cardiac pathologies in mice

Nicola Laura Diry, Megan Kay Wood, Taejoon Won, Monica Vladut Talor, Clarisse Lukban, Djahida Bedja, Nadan Wang, Hannah Kalinoski, Abdel Daoud, C. Conover Talbot Jr, Brian Leei Lin, Daniela Cihakova

Summary: Hypereosinophilic syndrome is a progressive disease that leads to organ damage, with cardiac pathology being the main cause of mortality. Understanding the mechanisms of eosinophil-mediated tissue damage can aid in therapeutic development.

ISCIENCE (2023)

Add to Collection

Article Multidisciplinary Sciences

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance

Agatha Lyczek, Benedict-Tilman Berger, Aziz M. Rangwala, YiTing Paung, Jessica Tom, Hannah Philipose, Jiaye Guo, Steven K. Albanese, Matthew B. Robers, Stefan Knapp, John D. Chodera, Markus A. Seeliger

Summary: Protein kinase inhibitors are potent anticancer drugs, but some patients develop resistance to these inhibitors, leading to suboptimal treatment outcomes. Mutations in the Bcr-Abl kinase domain contribute to resistance, with some altering drug-protein interactions and others located far from the drug-binding site still conferring resistance.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Chemistry, Analytical

Analysis of interactions between proteins and small-molecule drugs by a biosensor based on a graphene field-effect transistor

Shicai Xu, Tiejun Wang, Guofeng Liu, Zanxia Cao, Ludmila A. Frank, Shouzhen Jiang, Chao Zhang, Zhenhua Li, Vasilisa V. Krasitskaya, Qiang Li, Yujie Sha, Xiumei Zhang, Huilan Liu, Jihua Wang

Summary: The study synthesized large-area single-crystal graphene sheets for use in biosensors based on field-effect transistors (FET) to quantitatively analyze interactions between the imatinib drug and its target protein kinase Abl1. The G-FET biosensor showed excellent performance in recognizing imatinib at low concentrations and displayed a linear response to the logarithm of imatinib concentration. The graphene-based FET biosensor was also effective in quantifying mutations and dependencies in real-time, demonstrating its potential for analyzing interactions between proteins and low molecular weight drugs.

SENSORS AND ACTUATORS B-CHEMICAL (2021)

Add to Collection

Article Chemistry, Physical

A theoretical insight into the curing mechanism of phthalonitrile resins promoted by aromatic amines

Zuowei Chen, Liquan Wang, Jiaping Lin, Lei Du

Summary: This study investigated the curing mechanism of high-temperature phthalonitrile resins promoted by aromatic amines using density functional theory. The rate-determining step was found to be the nucleophilic addition of amines with nitrile groups on phthalonitrile, leading to amidine and isoindoline intermediates. Amines were crucial in promoting the intramolecular cyclization of amidine intermediates, facilitating the formation of isoindoline intermediates.

PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2021)

Add to Collection

Article Oncology

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Charles D. Blanke, Margaret von Mehren, Heikki Joensuu, Laura S. Mcgreevey, Chang-Jie Chen, Annick D. van den Abbeele, Brian J. Druker, Beate Kiese, Burton Eisenberg, Peter J. Roberts, Samuel Singer, Christopher D. M. Fletcher, Sandra Silberman, Sasa Dimitrijevic, Jonathan A. Fletcher

Summary: This study found that most GISTs have activating mutations in KIT or PDGFRA, and the occurrence of these mutations is related to clinical response to imatinib. PDGFRA mutations can explain the response and sensitivity to imatinib in some GISTs without KIT mutations.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

Hyacinthe Johnson-Ansah, Benjamin Maneglier, Francoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valerie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Benedicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stephane Bouchet, Francois-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot

Summary: This study evaluated the value of therapeutic drug monitoring (TDM) in imatinib treatment for patients with chronic myelogenous leukemia. The results showed that TDM strategy significantly increased the plasma concentration of imatinib and improved the treatment outcome for patients.

PHARMACEUTICS (2022)

Add to Collection

Article Oncology

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib

Mariarita Sciume, Giusy Ceparano, Cristina Eller-Vainicher, Sonia Fabris, Silvia Lonati, Giorgio Alberto Croci, Luca Baldini, Federica Irene Grifoni

Summary: Systemic mastocytosis (SM) is a rare neoplasm with heterogeneous clinical features, requiring individualized treatment. A patient with indolent SM developed a myeloid neoplasm with PDGFRA rearrangement, achieving complete remission with low-dose imatinib treatment.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

Maymona G. Abdelmagid, Aref Al-Kali, Mark R. Litzow, Kebede H. Begna, William J. Hogan, Mirinal S. Patnaik, Shahrukh K. Hashmi, Michelle A. Elliott, Hassan Alkhateeb, Omer S. Karrar, Farah Fleti, Mohammed H. Elnayir, Candido E. Rivera, Hemant S. Murthy, James M. Foran, Mohamed A. Kharfan-Dabaja, Talha Badar, David S. Viswanatha, Kaaren K. Reichard, Naseema Gangat, Ayalew Tefferi

Summary: We conducted a survey on the use of ponatinib as salvage therapy in a real-world setting of chronic phase chronic myeloid leukemia (CML-CP). The study showed that ponatinib improved the depth of response in patients with relapsed/refractory CML-CP. However, there was no apparent survival advantage for deeper responses and ABL1T315I mutation had a detrimental impact on survival. Prior exposure to nilotinib was associated with a higher risk of arterial occlusive events (AOEs).

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Polymer Science

Covalent Adaptable Networks with Rapid UV Response Based on Reversible Thiol-Ene Reactions in Silicone Elastomers

Miao Huo, Jerry G. Hu, David R. Clarke

Summary: PhotoCAN silicone elastomers show rapid and reversible changes in dynamic modulus at room temperature under UV illumination, thanks to the thiol-ene reaction. Through a combination of solid-state NMR, EPR, and rheometry measurements, it is found that the mechanical response is a result of dissociative, associative, and oxidation reactions. The reversible dissociative reaction, involving the cleavage of C-S bonds under UV in the presence of excess thiyl radicals, leads to abrupt drops in storage modulus. A slower termination process involving the formation of disulfide bonds by thiyl radicals is also observed. A kinetic model is developed to relate the rates of these reactions to the changes in storage modulus. These findings lay the foundation for the design of new photoresponsive covalently adaptive network materials at ambient temperature.

MACROMOLECULES (2023)

Add to Collection

Article Chemistry, Physical

Computer Simulations of the Dissociation Mechanism of Gleevec from Abl Kinase with Milestoning

Brajesh Narayan, Nicolae-Viorel Buchete, Ron Elber

Summary: This study used atomically detailed simulations within the Milestoning framework to investigate the molecular dissociation mechanism of Gleevec from Abl kinase. The researchers calculated the dissociation free energy profile, mean first passage time for unbinding, and explored the transition state ensemble of conformations. The study revealed that near the transition state, the highly conserved salt bridge between K217 and E286 is transiently broken.

JOURNAL OF PHYSICAL CHEMISTRY B (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes

Stefania Stella, Michele Massimino, Livia Manzella, Maria Stella Pennisi, Elena Tirro, Chiara Romano, Silvia Rita Vitale, Adriana Puma, Cristina Tomarchio, Sandra Di Gregorio, Giuseppe Alberto Palumbo, Paolo Vigneri

Summary: Hypereosinophilia is a heterogeneous condition with two major pathogenetic variants, myeloid or lymphocytic HES, which can lead to tissue or organ damage. Molecular genetic analyses can help characterize these syndromes and identify patients who may benefit from pharmacological targeted therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Hematology

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms

Jurgen Thiele, Hans Michael Kvasnicka, Attilio Orazi, Umberto Gianelli, Naseema Gangat, Alessandro M. Vannucchi, Tiziano Barbui, Daniel A. Arber, Ayalew Tefferi

Summary: A group of international experts met to update the World Health Organization classification system for hematopoietic tumors and introduced the new International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias. The focus of this review is on the ICC-2022 category of JAK2 mutation-prevalent myeloproliferative neoplasms (MPNs) and the importance of bone marrow morphology and genetic markers in disease classification and diagnostics.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Pathology

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms

Umberto Gianelli, Juergen Thiele, Attilio Orazi, Naseema Gangat, Alessandro M. Vannucchi, Ayalew Tefferi, Hans Michael Kvasnicka

Summary: The International Consensus Classification (ICC) of myeloid neoplasms, which was based on the efforts of pathologists, oncologists, and geneticists, aimed to update the 2017 World Health Organization classification system for hematopoietic tumors. The classification of myeloproliferative neoplasms (MPNs) underwent significant modifications, especially in terms of diagnostic methods and criteria.

VIRCHOWS ARCHIV (2023)

Add to Collection

Article Oncology

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study

Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-Maria Ribera, Renato Bassan, Andrey N. Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foa, Alessandro Rambaldi

Summary: This retrospective study included adult patients with B-cell ALL who were treated with blinatumomab for MRD+ or R/R B-cell ALL. The results showed significant treatment responses and survival benefits in both groups of patients.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Oncology

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project

Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A. Palumbo, Francesco Mannelli, Valerio De Stefano, Marco Ruggeri, Elena M. Elli, Roberta Zanotti, Oscar Borsani, Irene Bertozzi, Andrea Duminuco, Silvia Betti, Giuseppe Carli, Fabrizio Cavalca, Ilaria Tanasi, Elisa Rumi, Maria L. Randi, Bruno Garibaldi, Giuseppe G. Loscocco, Paola Guglielmelli, Alessandro M. Vannucchi

Summary: This study provides valuable insights into the efficacy and safety of ruxolitinib in a real-world cohort of Italian patients with myelofibrosis. The results highlight the importance of drug exposure, side effects, and treatment response in determining patient outcomes.

CANCER MEDICINE (2023)

Add to Collection

Article Hematology

A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

Giulia Maggioni, Matteo Bersanelli, Erica Travaglino, Ana Alfonso Pierola, Annika Kasprzak, Arnan Sangerman Montserrat, Elisabetta Sauta, Claudia Sala, Tommaso Matteuzzi, Manja Meggendorfer, Matteo Gnocchi, Lin--Pierre Zhao, Cristina Astrid Tentori, Kathrin Nachtkamp, Daniele Dall'Olio, Ettore Mosca, Marta Ubezio, Alessia Campagna, Antonio Russo, Giulia Rivoli, Massimo Bernardi, Lorenza Borin, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Elena Saba, Saverio D'Amico, Luca Lanino, Benedetta Tinterri, Francesca Re, Marilena Bicchieri, Laura Giordano, Giovanni Angelotti, Pierandrea Morandini, Anne Sophie Kubasch, Francesco Passamonti, Alessandro Rambaldi, Victor Savevski, Armando Santoro, Arjan A. van de Loosdrecht, Alice Brogi, Valeria Santini, Shahram Kordasti, Guillermo Sanz, Francesc Sole, Norbert Gattermann, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Ulrich Germing, Maria Diez--Campelo, Matteo G. Della Porta

Summary: This study aimed to describe sex diversity in myelodysplastic syndromes and incorporate sex information into clinical decision-making. The study found differences between men and women in terms of disease genotype, phenotype, and clinical outcomes. Moreover, new prognostic models that included sex information were developed and performed better than the revised International Prognostic Scoring System.

LANCET HAEMATOLOGY (2023)

Add to Collection

Review Hematology

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT

Nicola Polverelli, Juan Carlos Hernandez-Boluda, Tomasz Czerw, Tiziano Barbui, Mariella D'Adda, Hans Joachim Deeg, Markus Ditschkowski, Claire Harrison, Nicolaus Martin Kroger, Ruben Mesa, Francesco Passamonti, Francesca Palandri, Naveen Pemmaraju, Uday Popat, Damiano Rondelli, Alessandro Maria Vannucchi, Srdan Verstovsek, Marie Robin, Antonio Colecchia, Luigi Grazioli, Enrico Damiani, Domenico Russo, Jessica Brady, David Patch, Slawomir Blamek, Gandhi Laurent Damaj, Patrick Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha

Summary: Splenomegaly is a common complication in myelofibrosis patients and can negatively impact outcomes of allogeneic hematopoietic cell transplantation (HCT). This Position Paper provides a shared position statement on the management of splenomegaly before HCT. The assessment, prevalence, and clinical significance of splenomegaly are discussed, along with the need for therapeutic intervention. Specific scenarios, such as splanchnic vein thrombosis and COVID-19, are also addressed.

LANCET HAEMATOLOGY (2023)

Add to Collection

Editorial Material Hematology

JAK2 inhibitor treatment of anemia in myelofibrosis

Ayalew Tefferi, Alessandro M. Vannucchi

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Oncology

Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL

Federico Lussana, Gianluca Cavallaro, Pantaleo De Simone, Alessandro Rambaldi

Summary: In this review, the impact of novel immune therapies on the treatment of acute lymphoblastic leukemia (ALL) in children and adults was discussed. Results from trials evaluating the incorporation of these new drugs into frontline treatments show promising clinical benefit. Clinical conditions, such as high tumor burden or extra medullary relapse, still have poor clinical outcome despite the promising results. Combination of immunotherapies with chemotherapy in frontline treatment is being evaluated to increase the rate and depth of molecular remission. The use of tyrosine kinase inhibitors and immunotherapy in Ph-positive ALL has shown unprecedented rates of remission and long-term cure. The development of potentially curative treatment modalities for older ALL patients who cannot receive intensive chemotherapy is also highlighted.

CANCERS (2023)

Add to Collection

Article Biology

High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias

Alberto Magi, Gianluca Mattei, Alessandra Mingrino, Chiara Caprioli, Chiara Ronchini, GianMaria Frige, Roberto Semeraro, Davide Bolognini, Alessandro Rambaldi, Anna Candoni, Emanuela Colombo, Luca Mazzarella, Pier Giuseppe Pelicci

Summary: DNA methylation patterns in sparse CpG regions drive chemoresistance in Acute Myeloid Leukemia patients.

COMMUNICATIONS BIOLOGY (2023)

Add to Collection

Correction Biology

High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias (vol 6, 382, 2023)

Alberto Magi, Gianluca Mattei, Alessandra Mingrino, Chiara Caprioli, Chiara Ronchini, Gianmaria Frige, Roberto Semeraro, Davide Bolognini, Alessandro Rambaldi, Anna Candoni, Emanuela Colombo, Luca Mazzarella, Pier Giuseppe Pelicci

COMMUNICATIONS BIOLOGY (2023)

Add to Collection

Editorial Material Hematology

Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement

Giuseppe G. Loscocco, Stefano Ascani, Francesco Mannelli, Magda Zanelli, Giada Rotunno, Raffaella Santi, Alessandro M. Vannucchi

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Editorial Material Oncology

Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms Friend and Enemy, Depending on Circumstances

Alessandro Maria Vannucchi, Paola Guglielmelli

JACC: CARDIOONCOLOGY (2023)

Add to Collection

Correction Medicine, General & Internal

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study (vol 401, pg 269, 2023)

S. Verstovsek, A. T. Gerds, A. M. Vannucchi

LANCET (2023)

Add to Collection

Article Medicine, General & Internal

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srdan Verstovsek, Aaron T. Gerds, Alessandro M. Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T. Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C. Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung -Soo Yoon, Vikas Gupta, Jean -Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N. Harrison, Barbara J. Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben Mesa

Summary: This study aimed to compare the clinical effects of momelotinib and danazol in patients with intermediate or high-risk myelofibrosis. The results showed that momelotinib can significantly improve myelofibrosis-associated symptoms, anemia measures, and spleen response compared to danazol, with favorable safety.

LANCET (2023)

Add to Collection

Article Oncology

The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients

Tiziano Barbui, Alessandra Carobbio, Juergen Thiele, Naseema Gangat, Elisa Rumi, Alessandro Rambaldi, Alessandro M. Vannucchi, Ayalew Tefferi

Summary: This study applied a parametric Markov model to investigate the impact of incident thrombosis on death or disease progression in patients with polycythemia vera. The results showed that thrombosis was associated with a higher probability of death and had different effects on arterial and venous thrombosis.

BLOOD CANCER JOURNAL (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.